| SC 13G/A | 2024-02-14 | Point72 Asset Management, L.P. | Vistagen Therapeutics, Inc. | 822,334 | 3.0% | EDGAR |
| SC 13G/A | 2024-02-14 | CITADEL ADVISORS LLC | Vistagen Therapeutics, Inc. | - | 5.6% | EDGAR |
| SC 13G/A | 2024-02-14 | GREAT POINT PARTNERS LLC | Vistagen Therapeutics, Inc. | 2,792,927 | 10.0% | EDGAR |
| SC 13G | 2024-02-14 | Nantahala Capital Management, LLC | Vistagen Therapeutics, Inc. | 2,797,588 | 9.9% | EDGAR |
| SC 13G | 2024-02-13 | VANGUARD GROUP INC | Vistagen Therapeutics, Inc. | 1,834,512 | 6.8% | EDGAR |
| SC 13G | 2023-10-16 | BIOTECHNOLOGY VALUE FUND L P | Vistagen Therapeutics, Inc. | 1,437,104 | 5.2% | EDGAR |
| SC 13G | 2023-10-16 | CITADEL ADVISORS LLC | Vistagen Therapeutics, Inc. | - | 5.6% | EDGAR |
| SC 13G | 2023-10-16 | TCG Crossover GP II, LLC | Vistagen Therapeutics, Inc. | 2,033,012 | 7.5% | EDGAR |
| SC 13G | 2023-10-12 | GREAT POINT PARTNERS LLC | Vistagen Therapeutics, Inc. | 2,792,927 | 10.0% | EDGAR |
| SC 13G/A | 2023-10-06 | COMMODORE CAPITAL LP | Vistagen Therapeutics, Inc. | 2,367,884 | 9.9% | EDGAR |
| SC 13G | 2023-10-05 | Point72 Asset Management, L.P. | Vistagen Therapeutics, Inc. | 1,565,829 | 5.6% | EDGAR |
| SC 13G | 2023-08-09 | COMMODORE CAPITAL LP | Vistagen Therapeutics, Inc. | 1,575,000 | 19.7% | EDGAR |
| SC 13G/A | 2023-07-07 | BlackRock Inc. | Vistagen Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | ACUTA CAPITAL PARTNERS, LLC | VistaGen Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | ORBIMED ADVISORS LLC | VistaGen Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | COMMODORE CAPITAL LP | VistaGen Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-01 | FRANKLIN RESOURCES INC | VistaGen Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-01 | BlackRock Inc. | VistaGen Therapeutics, Inc. | 12,267,968 | 5.9% | EDGAR |
| SC 13D/A | 2022-08-12 | Growth Equity Opportunities 17, LLC | VistaGen Therapeutics, Inc. | - | - | EDGAR |
| SC 13G/A | 2022-07-08 | Venrock Healthcare Capital Partners II, L.P. | VistaGen Therapeutics, Inc. | 20,697,286 | 10.0% | EDGAR |